Discovery of antibodies highly selective for toxic α-synuclein conformations may require more than just classical methods if pharma and life sciences want to make faster progress against Parkinson's disease.. [
more ]
by Dr. Neil Cashman of ProMIS
There are plenty of new areas to explore in therapeutic options for all diseases and conditions that vex us, but are we straying too far from reliable ground and ignoring good options in the process?.. [
more ]
by Peter T. Kissinger
Does a new treatment specifically targeting postpartum depression signal new progress in other niche areas of depression as well as treating the illness more broadly?.. [
more ]
